NCT07074834View on ClinicalTrials.gov

Metoprolol and Trimetazidine for Coronary Heart Disease With Angina

NACompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

December 31, 2022

Conditions

Coronary Heart Disease (CHD)

Interventions

DRUG

Metoprolol Succinate Sustained-Release Tablets

Oral administration. Dose was 23.75 mg once daily for the first two weeks, then increased to 47.50 mg once daily.

DRUG

Trimetazidine

Oral administration. Dose was one tablet twice daily.

DRUG

Routine Drug Therapy

Included oral nitroglycerin tablets (0.5 mg twice daily), aspirin enteric-coated tablets (0.1 g once daily), and rosuvastatin calcium tablets (10 mg three times daily).

Trial Locations (1)

442000

Renmin Hospital, Hubei University of Medicine, Shiyan

All Listed Sponsors

lead

Shiyan City Renmin Hospital

OTHER_GOV

NCT07074834 - Metoprolol and Trimetazidine for Coronary Heart Disease With Angina | Biotech Hunter | Biotech Hunter